EGFR isoforms and gene regulation in human endometrial cancer cells

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Albitar, Lina ^a,c   Pickett, Gavin ^a   Morgan, Marilee ^a,d   Wilken, Jason A ^b   Maihle, Nita J ^b   Leslie, Kimberly K ^a,e  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MIND RESEARCH NETWORK   (United States)

^e UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUAL SPECIFICITY PHOSPHATASE 6; EARLY GROWTH RESPONSE FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GLUCOCORTICOID RECEPTOR DNA BINDING FACTOR 1; ISOPROTEIN; NUCLEIC ACID BINDING PROTEIN; SPHINGOSINE KINASE 2; UNCLASSIFIED DRUG; PRIMER DNA;

ARTICLE; CANCER CELL; CONTROLLED STUDY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FEMALE; GENE CONTROL; GENE EXPRESSION REGULATION; GENE MUTATION; GENE REGULATORY NETWORK; HUMAN; HUMAN CELL; PROTEIN DOMAIN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; WILD TYPE; AGAR GEL ELECTROPHORESIS; DNA MICROARRAY; ENDOMETRIUM TUMOR; EXON; GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

BASE SEQUENCE; CELL LINE, TUMOR; DNA PRIMERS; ELECTROPHORESIS, AGAR GEL; ENDOMETRIAL NEOPLASMS; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN ISOFORMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77955147943     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-166     Document Type: Article

References (40)

1. Platz CE, Benda JA. Female genital tract cancer. Cancer 1995, 75:270-294. 10.1002/1097-0142(19950101)75:1+<270::AID-CNCR2820751312>3.0.CO;2-D, 8001001.
2. Rose PG. Endometrial carcinoma. N Engl J Med 1996, 335:640-649. 10.1056/NEJM199608293350907, 8692240.
3. Arnett-Mansfield RL, DeFazio A, Mote PA, Clarke CL. Subnuclear distribution of progesterone receptors A and B in normal and malignant endometrium. J Clin Endocrinol Metab 2004, 89:1429-1442. 10.1210/jc.2003-031111, 15001645.
4. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995, 26:1268-1274. 10.1016/0046-8177(95)90204-X, 7590703.
5. Sherman ME, Sturgeon S, Brinton L, Kurman RJ. Endometrial cancer chemoprevention: implications of diverse pathways of carcinogenesis. J Cell Biochem Suppl 1995, 23:160-164. 10.1002/jcb.240590921, 8747391.
6. Albitar L, Pickett G, Morgan M, Davies S, Leslie KK. Models representing type I and type II human endometrial cancers: Ishikawa H and Hec50co cells. Gynecologic oncology 2007, 106:52-64. 10.1016/j.ygyno.2007.02.033, 17490735.
7. Leslie KK, Kumar NS, Richer J, Owen G, Takimoto G, Horwitz KB, Lange C. Differential expression of the A and B isoforms of progesterone receptor in human endometrial cancer cells. Only progesterone receptor B is induced by estrogen and associated with strong transcriptional activation. Ann N Y Acad Sci 1997, 828:17-26. 10.1111/j.1749-6632.1997.tb48520.x, 9329820.
8. Kumar NS, Richer J, Owen G, Litman E, Horwitz KB, Leslie KK. Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action. Cancer Res 1998, 58:1860-1865.
9. Dai D, Albitar L, Nguyen T, Laidler LL, Singh M, Leslie KK. A therapeutic model for advanced endometrial cancer: systemic progestin in combination with local adenoviral-mediated progesterone receptor expression. Mol Cancer Ther 2005, 4:169-175.
10. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004, 59:21-26.
11. Konecny GE, Santos L, Winterhoff B, Hatmal M, Keeney GL, Mariani A, Jones M, Neuper C, Thomas B, Muderspach L, et al. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br J Cancer 2009, 100:89-95. 10.1038/sj.bjc.6604814, 2634683, 19088718.
12. Albitar L, Laidler LL, Abdallah R, Leslie KK. Regulation of signaling phosphoproteins by epidermal growth factor and Iressa (ZD1839) in human endometrial cancer cells that model type I and II tumors. Mol Cancer Ther 2005, 4:1891-1899. 10.1158/1535-7163.MCT-05-0274, 16373704.
13. Albitar L, Carter MB, Davies S, Leslie KK. Consequences of the loss of p53, RB1, and PTEN: relationship to gefitinib resistance in endometrial cancer. Gynecologic oncology 2007, 106:94-104. 10.1016/j.ygyno.2007.03.006, 17490733.
14. Ishii S, Xu YH, Stratton RH, Roe BA, Merlino GT, Pastan I. Characterization and sequence of the promoter region of the human epidermal growth factor receptor gene. Proc Natl Acad Sci USA 1985, 82:4920-4924. 10.1073/pnas.82.15.4920, 390469, 2991899.
15. Reiter JL, Maihle NJ. A 1.8 kb alternative transcript from the human epidermal growth factor receptor gene encodes a truncated form of the receptor. Nucleic Acids Res 1996, 24:4050-4056. 10.1093/nar/24.20.4050, 146204, 8918811.
16. Reiter JL, Threadgill DW, Eley GD, Strunk KE, Danielsen AJ, Sinclair CS, Pearsall RS, Green PJ, Yee D, Lampland AL, et al. Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms. Genomics 2001, 71:1-20. 10.1006/geno.2000.6341, 11161793.
17. Reiter JL, Maihle NJ. Characterization and expression of novel 60-kDa and 110-kDa EGFR isoforms in human placenta. Ann N Y Acad Sci 2003, 995:39-47. 10.1111/j.1749-6632.2003.tb03208.x, 12814937.
18. Baron AT, Cora EM, Lafky JM, Boardman CH, Buenafe MC, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2003, 12:103-113.
19. Lafky JM, Wilken JA, Baron AT, Maihle NJ. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta 2008, 1785:232-265.
20. Flickinger TW, Maihle NJ, Kung HJ. An alternatively processed mRNA from the avian c-erbB gene encodes a soluble, truncated form of the receptor that can block ligand-dependent transformation. Mol Cell Biol 1992, 12:883-893. 364322, 1732751.
21. Basu A, Raghunath M, Bishayee S, Das M. Inhibition of tyrosine kinase activity of the epidermal growth factor (EGF) receptor by a truncated receptor form that binds to EGF: role for interreceptor interaction in kinase regulation. Mol Cell Biol 1989, 9:671-677. 362644, 2785240.
22. Lee H, Akita RW, Sliwkowski MX, Maihle NJ. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4. Cancer Res 2001, 61:4467-4473.
23. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD, Morse D, Abraham S, Rahman A, Liang C, Lostritto R, et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004, 10:1212-1218. 10.1158/1078-0432.CCR-03-0564, 14977817.
24. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139. 10.1056/NEJMoa040938, 15118073.
25. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500. 10.1126/science.1099314, 15118125.
26. Christensen TA, Reiter JL, Baron AT, Maihle NJ. Generation and characterization of polyclonal antibodies specific for human p110 sEGFR. Hybridoma and hybridomics 2002, 21:183-189. 10.1089/153685902760173908, 12165144.
27. Baron AT, Huntley BK, Lafky JM, Reiter JL, Liebenow J, McCormick DJ, Ziesmer SC, Roche PC, Maihle NJ. Monoclonal antibodies specific for peptide epitopes of the epidermal growth factor receptor's extracellular domain. Hybridoma 1997, 16:259-271. 10.1089/hyb.1997.16.259, 9219036.
28. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, Chen RO, Brownstein BH, Cobb JP, Tschoeke SK, et al. A network-based analysis of systemic inflammation in humans. Nature 2005, 437:1032-1037. 10.1038/nature03985, 16136080.
29. Baron AT, Lafky JM, Boardman CH, Balasubramaniam S, Suman VJ, Podratz KC, Maihle NJ. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 1999, 8:129-137.
30. Gregorc V, Ceresoli GL, Floriani I, Spreafico A, Bencardino KB, Ludovini V, Pistola L, Mihaylova Z, Tofanetti FR, Ferraldeschi M, et al. Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004, 10:6006-6012. 10.1158/1078-0432.CCR-03-0770, 15447984.
31. Zampino MG, Magni E, Santoro L, Zorzino L, Dell'Orto P, Sonzogni A, Fazio N, Monfardini L, Chiappa A, Biffi R, de Braud F. Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib?. Cancer Chemother Pharmacol 2008, 63:139-148. 10.1007/s00280-008-0722-x, 18327586.
32. Lafky JM, Baron AT, Cora EM, Hillman DW, Suman VJ, Perez EA, Ingle JN, Maihle NJ. Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole. Cancer Res 2005, 65:3059-3062.
33. Baron AT, Wilken JA, Haggstrom DE, Goodrich ST, Maihle NJ. Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer. IDrugs 2009, 12:302-308.
34. Berasain C, Perugorria MJ, Latasa MU, Castillo J, Goni S, Santamaria M, Prieto J, Avila MA. The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med (Maywood) 2009, 234:713-725. 10.3181/0901-MR-12, 19429859.
35. Huang Y, Tan M, Gosink M, Wang KK, Sun Y. Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis. Cancer Res 2002, 62:2913-2922.
36. Chang SJ, Wang TY, Tsai CY, Hu TF, Chang MD, Wang HW. Increased epithelial stem cell traits in advanced endometrial endometrioid carcinoma. BMC Genomics 2009, 10:613. 10.1186/1471-2164-10-613, 2810306, 20015385.
37. Wang M, Hu Y, Stearns ME. RPS2: a novel therapeutic target in prostate cancer. J Exp Clin Cancer Res 2009, 28:6. 10.1186/1756-9966-28-6, 2633276, 19138403.
38. Hammarsund M, Lerner M, Zhu C, Merup M, Jansson M, Gahrton G, Kluin-Nelemans H, Einhorn S, Grander D, Sangfelt O, Corcoran M. Disruption of a novel ectodermal neural cortex 1 antisense gene, ENC-1AS and identification of ENC-1 overexpression in hairy cell leukemia. Hum Mol Genet 2004, 13:2925-2936. 10.1093/hmg/ddh315, 15459180.
39. Nakamura Y, Migita T, Hosoda F, Okada N, Gotoh M, Arai Y, Fukushima M, Ohki M, Miyata S, Takeuchi K, et al. Kruppel-like factor 12 plays a significant role in poorly differentiated gastric cancer progression. Int J Cancer 2009, 125:1859-1867. 10.1002/ijc.24538, 19588488.
40. Xue Y, Bi F, Zhang X, Zhang S, Pan Y, Liu N, Shi Y, Yao X, Zheng Y, Fan D. Role of Rac1 and Cdc42 in hypoxia induced p53 and von Hippel-Lindau suppression and HIF1alpha activation. Int J Cancer 2006, 118:2965-2972. 10.1002/ijc.21763, 16395716.